Eli Lilly reduces costs of Zepbound through its LillyDirect platform

Eli Lilly on Monday announced new price cuts for its popular weight-loss drug Zepbound, expanding access for patients and increasing use of the company’s digital healthcare platform, LillyDirect.

Single-dose vials of Zepbound purchased through the Zepbound Self Pay Journey program on LillyDirect will now cost $299 per month — up from $349 — for patients with a valid prescription.

The 5-milligram dose will also be priced at $399 per month, down from $499. All other approved doses will cost $449 per month, Eli Lilly said.

LillyDirect, which launched in early 2024, allows certain consumers who are uninsured, underinsured or lack adequate coverage to access Zepbound and Moonjaro directly from Eli Lilly through the Zepbound Self Pay Journey program.

Trump announces an agreement with drug makers to reduce the cost of weight-loss drugs

Regular monthly prices when not purchased through the Zepbound Self-Pay Journey program are $599 for 7.5 milligrams, $699 for 10 milligrams, $849 for 12.5 milligrams, and $1,049 for 15 milligrams, according to the pharmaceutical giant.

WEGOVY, OZEMPIC: Barriers to accessing these weight loss medications

The move comes less than a month after Eli Lilly announced plans to lower prices for its Zepbound multi-dose pens, although that is still subject to FDA approval. Starting in April 2026, Medicare patients will pay no more than $50 a month for Zepbound sold in a multi-dose pen and for orforgliliprone, Lilly’s once-daily weight-loss pill, as long as both drugs are approved by the food and Drug Administration.

Eli Lilly’s competitor Novo Nordisk makes its own weight-loss drugs, Wegovy and Ozempic. (Shelby Knowles/Bloomberg via Getty Images)

For self-pay patients, the Zepbound multi-dose pen will be available at the lowest dose for $299, with additional doses up to $449. When patients refill their prescription for the multi-dose pen on the LillyDirect digital health platform, they will pay no more than $449. The company previously said Orforglipron will be available at the lowest dose starting at $149 with additional doses up to $399.

Major health insurance companies are trimming their Medicare Advantage offerings in 2026

Eli Lilly and Novo Nordisk have launched their direct-to-consumer platforms with the goal of expanding patient access by reducing the barriers new patients face. While both companies say these platforms will help new patients access their medications, they also give each company a competitive advantage.

Get FOX Business on the go by clicking here

Novo Nordisk launched its platform, NovoCare Pharmacy, in March, allowing patients who cannot afford the standard list price or lack insurance coverage for the weight-loss drugs Wegovy and Ozempic.